Pancreatitis risk with DPP4 inhibitors

Acute pancreatitis is now listed as a possible adverse effect of all dipeptidyl peptidase 4 (DPP4) inhibitors ('gliptins').

The mechanism by which DPP4 inhibitors might increase the risk of pancreatitis is unknown | SCIENCE PHOTO LIBRARY
The mechanism by which DPP4 inhibitors might increase the risk of pancreatitis is unknown | SCIENCE PHOTO LIBRARY

Drugs of this class, which are used in the treatment of type II diabetes, include Galvus (vildagliptin), Januvia (sitagliptin), Onglyza (saxagliptin), Trajenta (linagliptin), and the combination tablets Eucreas (metformin + vildagliptin), Janumet (metformin + sitagliptin) and Jentadueto (metformin + linagliptin).

When to suspect pancreatitis

Characteristic symptoms of acute pancreatitis include persistent, severe abdominal pain, sometimes radiating to the back. The MHRA advises that all patients taking a DPP4 inhibitor should be informed of these symptoms and encouraged to report any occurrence. Treatment should be discontinued if pancreatitis is suspected. 

Follow MIMS on Twitter


Read these next

Vipidia and Vipdomet: two new products for type II diabetes

Vipidia and Vipdomet: two new products for type II diabetes

Takeda has launched Vipidia and Vipdomet, two new products...

News in brief - October 2013

News in brief - October 2013

Other new launches, licence changes and updates relevant...

Onglyza approved for triple oral therapy

Onglyza approved for triple oral therapy

Onglyza (saxagliptin) can now be used in combination...

Komboglyze: new hypoglycaemic combination

Komboglyze: new hypoglycaemic combination

Bristol-Myers Squibb and AstraZeneca have launched...

Licence extensions for linagliptin and vildagliptin

Licence extensions for linagliptin and vildagliptin

The dipeptidyl peptidase 4 (DPP4) inhibitors linagliptin...

Jentadueto: new combination tablet for type II diabetes

Jentadueto: new combination tablet for type II diabetes

Jentadueto (linagliptin/metformin) is a new fixed-dose...

Trajenta launched for type II diabetes

Trajenta launched for type II diabetes

Trajenta (linagliptin) is a new once daily DPP4 inhibitor...

Onglyza approved for use in renal impairment

Onglyza approved for use in renal impairment

The licence for Onglyza (saxagliptin) has been extended...


MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.